Clinical Trial: STUDY OF THE EFFECTS OF L. CASEI DG(R) (ENTEROLACTIS BABY) IN HEALTHY PRETERM AND FULL-TERM INFANTS.

U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07882537) titled 'STUDY OF THE EFFECTS OF L. CASEI DG(R) (ENTEROLACTIS BABY) IN HEALTHY PRETERM AND FULL-TERM INFANTS.' on Sept. 23.

Brief Summary: The goal of this clinical trial was to learn whether giving Enterolactis Baby(R), a probiotic food supplement containing Lactobacillus casei DG(R) (under the new taxonomical denomination: Lacticaseibacillus paracasei DG, CNCM I-1572), to healthy preterm and full-term infants from approximately 48 hours after birth for 28 days affected the bacteria naturally living in the infants' gut.

The main question it aims to answer is:

Does taking Enterolactis Baby(R) for 28 days change the amount of L. paracasei D...